Mesoblast Anticipates FDA Decisions, Manages Finances
Company Announcements

Mesoblast Anticipates FDA Decisions, Manages Finances

Mesoblast (MESO) has released an update.

Mesoblast Limited is poised for a potential FDA approval for Ryoncil, aimed at treating children with acute GVHD, after a successful BLA resubmission. The company also progresses with a Phase 3 trial for chronic inflammatory low back pain and seeks accelerated FDA approval for Revascor in heart failure patients. Amid these advancements, Mesoblast has effectively reduced its cash expenditure, maintaining a robust cash balance while prioritizing key programs and preparing for Ryoncil’s commercial launch.

For further insights into MESO stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskMesoblast Poised for Breakthroughs in Cellular Medicine
TheFlyMesoblast management to meet with Maxim
TipRanks Auto-Generated NewsdeskMesoblast Advances Cellular Medicines Amid FDA Hopes
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App